APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting PEG-rhG-CSF

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Long-acting PEG-rhG-CSF Industry Growth and Trends Forecast to 2032

23 December 2025101 pages

Choose your research edition.

Industry ResearchLong-acting PEG-rhG-CSF Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting PEG-rhG-CSF Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Long-acting PEG-rhG-CSF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting PEG-rhG-CSF Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting PEG-rhG-CSF Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting PEG-rhG-CSF market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Long-acting PEG-rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Long-acting PEG-rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting PEG-rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Long-acting PEG-rhG-CSF include CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi, Amgen Inc. and Coherus BioSciences, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Long-acting PEG-rhG-CSF market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Long-acting PEG-rhG-CSF market size, estimates, and forecasts are presented in terms of sales volume (units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Long-acting PEG-rhG-CSF market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Long-acting PEG-rhG-CSF.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Long-acting PEG-rhG-CSF market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Long-acting PEG-rhG-CSF Market by Company

CSPC

Sandoz (Novartis)

Qilu Pharmaceutical

Mylan

Pfizer

Jiangsu Hengrui Medicine

Fresenius Kabi

Amgen Inc.

Coherus BioSciences, Inc.

Biocon Biologics Inc.

Long-acting PEG-rhG-CSF Segment by Type

Innovative Drugs

Generic Drugs

Long-acting PEG-rhG-CSF Segment by Application

Blood Disorders

Neoplastic Diseases

Others

Long-acting PEG-rhG-CSF Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting PEG-rhG-CSF market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting PEG-rhG-CSF and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting PEG-rhG-CSF.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Long-acting PEG-rhG-CSF manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Long-acting PEG-rhG-CSF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Innovative Drugs Table 2. Major Company of Generic Drugs Table 3. Global Long-acting PEG-rhG-CSF Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 5. Global Long-acting PEG-rhG-CSF Sales Market Share in Volume by Type (2021-2026) Table 6. Global Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 7. Global Long-acting PEG-rhG-CSF Sales Market Share in Value by Type (2021-2026) Table 8. Global Long-acting PEG-rhG-CSF Price by Type (2021-2026) & (USD/unit) Table 9. Global Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (units) Table 10. Global Long-acting PEG-rhG-CSF Sales Market Share in Volume by Type (2027-2032) Table 11. Global Long-acting PEG-rhG-CSF Sales by Type (2027-2032) & (US$ Million) Table 12. Global Long-acting PEG-rhG-CSF Sales Market Share in Value by Type (2027-2032) Table 13. Global Long-acting PEG-rhG-CSF Price by Type (2027-2032) & (USD/unit) Table 14. North America Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 15. North America Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 17. Europe Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 19. Asia-Pacific Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 21. Latin America Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (units) Table 23. Middle East and Africa Long-acting PEG-rhG-CSF Sales by Type (2021-2026) & (US$ Million) Table 24. Long-acting PEG-rhG-CSF Industry Trends Table 25. Long-acting PEG-rhG-CSF Industry Drivers Table 26. Long-acting PEG-rhG-CSF Industry Opportunities and Challenges Table 27. Long-acting PEG-rhG-CSF Industry Restraints Table 28. Global Long-acting PEG-rhG-CSF Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Long-acting PEG-rhG-CSF Revenue Market Share by Company (2021-2026) Table 30. Global Long-acting PEG-rhG-CSF Sales by Company (2021-2026) & (units) Table 31. Global Long-acting PEG-rhG-CSF Sales Share by Company (2021-2026) Table 32. Global Long-acting PEG-rhG-CSF Market Price by Company (2021-2026) & (USD/unit) Table 33. Global Long-acting PEG-rhG-CSF Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Long-acting PEG-rhG-CSF Major Company Production Sites and Headquarters Table 35. Global Long-acting PEG-rhG-CSF Company, Product Type & Application Table 36. Global Long-acting PEG-rhG-CSF Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Long-acting PEG-rhG-CSF by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Long-acting PEG-rhG-CSF Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Long-acting PEG-rhG-CSF Sales by Region (2021-2026) & (units) Table 41. Global Long-acting PEG-rhG-CSF Sales Market Share in Volume by Region (2021-2026) Table 42. Global Long-acting PEG-rhG-CSF Sales by Region (2021-2026) & (US$ Million) Table 43. Global Long-acting PEG-rhG-CSF Sales Market Share in Value by Region (2021-2026) Table 44. Global Long-acting PEG-rhG-CSF Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 45. Global Long-acting PEG-rhG-CSF Sales by Region (2027-2032) & (units) Table 46. Global Long-acting PEG-rhG-CSF Sales Market Share in Volume by Region (2027-2032) Table 47. Global Long-acting PEG-rhG-CSF Sales by Region (2027-2032) & (US$ Million) Table 48. Global Long-acting PEG-rhG-CSF Sales Market Share in Value by Region (2027-2032) Table 49. Global Long-acting PEG-rhG-CSF Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 50. Global Long-acting PEG-rhG-CSF Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 52. Global Long-acting PEG-rhG-CSF Sales Market Share in Volume by Application (2021-2026) Table 53. Global Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 54. Global Long-acting PEG-rhG-CSF Sales Market Share in Value by Application (2021-2026) Table 55. Global Long-acting PEG-rhG-CSF Price by Application (2021-2026) & (USD/unit) Table 56. Global Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (units) Table 57. Global Long-acting PEG-rhG-CSF Sales Market Share in Volume by Application (2027-2032) Table 58. Global Long-acting PEG-rhG-CSF Sales by Application (2027-2032) & (US$ Million) Table 59. Global Long-acting PEG-rhG-CSF Sales Market Share in Value by Application (2027-2032) Table 60. Global Long-acting PEG-rhG-CSF Price by Application (2027-2032) & (USD/unit) Table 61. North America Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 62. North America Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 64. Europe Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 66. Asia-Pacific Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 68. Latin America Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (units) Table 70. Middle East and Africa Long-acting PEG-rhG-CSF Sales by Application (2021-2026) & (US$ Million) Table 71. CSPC Company Information Table 72. CSPC Business Overview Table 73. CSPC Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. CSPC Long-acting PEG-rhG-CSF Product Portfolio Table 75. CSPC Recent Development Table 76. Sandoz (Novartis) Company Information Table 77. Sandoz (Novartis) Business Overview Table 78. Sandoz (Novartis) Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Sandoz (Novartis) Long-acting PEG-rhG-CSF Product Portfolio Table 80. Sandoz (Novartis) Recent Development Table 81. Qilu Pharmaceutical Company Information Table 82. Qilu Pharmaceutical Business Overview Table 83. Qilu Pharmaceutical Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Qilu Pharmaceutical Long-acting PEG-rhG-CSF Product Portfolio Table 85. Qilu Pharmaceutical Recent Development Table 86. Mylan Company Information Table 87. Mylan Business Overview Table 88. Mylan Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Mylan Long-acting PEG-rhG-CSF Product Portfolio Table 90. Mylan Recent Development Table 91. Pfizer Company Information Table 92. Pfizer Business Overview Table 93. Pfizer Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Pfizer Long-acting PEG-rhG-CSF Product Portfolio Table 95. Pfizer Recent Development Table 96. Jiangsu Hengrui Medicine Company Information Table 97. Jiangsu Hengrui Medicine Business Overview Table 98. Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Product Portfolio Table 100. Jiangsu Hengrui Medicine Recent Development Table 101. Fresenius Kabi Company Information Table 102. Fresenius Kabi Business Overview Table 103. Fresenius Kabi Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Fresenius Kabi Long-acting PEG-rhG-CSF Product Portfolio Table 105. Fresenius Kabi Recent Development Table 106. Amgen Inc. Company Information Table 107. Amgen Inc. Business Overview Table 108. Amgen Inc. Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Amgen Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 110. Amgen Inc. Recent Development Table 111. Coherus BioSciences, Inc. Company Information Table 112. Coherus BioSciences, Inc. Business Overview Table 113. Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 115. Coherus BioSciences, Inc. Recent Development Table 116. Biocon Biologics Inc. Company Information Table 117. Biocon Biologics Inc. Business Overview Table 118. Biocon Biologics Inc. Long-acting PEG-rhG-CSF Sales (units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Biocon Biologics Inc. Long-acting PEG-rhG-CSF Product Portfolio Table 120. Biocon Biologics Inc. Recent Development Table 121. North America Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 122. North America Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 123. North America Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2026) Table 124. North America Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 125. North America Long-acting PEG-rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 126. North America Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Long-acting PEG-rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Long-acting PEG-rhG-CSF Market Share by Country (2021-2026) Table 129. North America Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Long-acting PEG-rhG-CSF Market Share Forecast by Country (2027-2032) Table 131. Europe Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 132. Europe Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 133. Europe Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2026) Table 134. Europe Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 135. Europe Long-acting PEG-rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Long-acting PEG-rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Long-acting PEG-rhG-CSF Market Share by Country (2021-2026) Table 139. Europe Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Long-acting PEG-rhG-CSF Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 143. Asia-Pacific Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 145. Asia-Pacific Long-acting PEG-rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Long-acting PEG-rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Long-acting PEG-rhG-CSF Market Share by Country (2021-2026) Table 149. Asia-Pacific Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Long-acting PEG-rhG-CSF Market Share Forecast by Country (2027-2032) Table 151. Latin America Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 152. Latin America Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 153. Latin America Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2026) Table 154. Latin America Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 155. Latin America Long-acting PEG-rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Long-acting PEG-rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Long-acting PEG-rhG-CSF Market Share by Country (2021-2026) Table 159. Latin America Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Long-acting PEG-rhG-CSF Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (units): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Long-acting PEG-rhG-CSF Sales by Country (2021-2026) & (units) Table 163. Middle East and Africa Long-acting PEG-rhG-CSF Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032) & (units) Table 165. Middle East and Africa Long-acting PEG-rhG-CSF Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Long-acting PEG-rhG-CSF Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Long-acting PEG-rhG-CSF Market Share by Country (2021-2026) Table 169. Middle East and Africa Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Long-acting PEG-rhG-CSF Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Long-acting PEG-rhG-CSF Distributors List Table 174. Long-acting PEG-rhG-CSF Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Long-acting PEG-rhG-CSF Image Figure 2. Global Long-acting PEG-rhG-CSF Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting PEG-rhG-CSF Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting PEG-rhG-CSF Sales (2021-2032) & (units) Figure 5. Innovative Drugs Image Figure 6. Global Innovative Drugs Sales YoY Growth (2021-2032) & (units) Figure 7. Generic Drugs Image Figure 8. Global Generic Drugs Sales YoY Growth (2021-2032) & (units) Figure 9. Global Long-acting PEG-rhG-CSF Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Long-acting PEG-rhG-CSF Market Share by Type 2025 VS 2032 Figure 11. North America Long-acting PEG-rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 12. North America Long-acting PEG-rhG-CSF Sales Market Share in Value by Type in 2025 Figure 13. Europe Long-acting PEG-rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 14. Europe Long-acting PEG-rhG-CSF Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Long-acting PEG-rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Long-acting PEG-rhG-CSF Sales Market Share in Value by Type in 2025 Figure 17. Latin America Long-acting PEG-rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Long-acting PEG-rhG-CSF Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Long-acting PEG-rhG-CSF Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Long-acting PEG-rhG-CSF Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Long-acting PEG-rhG-CSF Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Blood Disorders Image Figure 24. Global Blood Disorders Sales YoY Growth (2021-2032) & (units) Figure 25. Neoplastic Diseases Image Figure 26. Global Neoplastic Diseases Sales YoY Growth (2021-2032) & (units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (units) Figure 29. Global Long-acting PEG-rhG-CSF Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Long-acting PEG-rhG-CSF Market Share by Application 2025 VS 2032 Figure 31. North America Long-acting PEG-rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 32. North America Long-acting PEG-rhG-CSF Sales Market Share in Value by Application in 2025 Figure 33. Europe Long-acting PEG-rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 34. Europe Long-acting PEG-rhG-CSF Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Long-acting PEG-rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Long-acting PEG-rhG-CSF Sales Market Share in Value by Application in 2025 Figure 37. Latin America Long-acting PEG-rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Long-acting PEG-rhG-CSF Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Long-acting PEG-rhG-CSF Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Long-acting PEG-rhG-CSF Sales Market Share in Value by Application in 2025 Figure 41. North America Long-acting PEG-rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 42. North America Long-acting PEG-rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Long-acting PEG-rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Long-acting PEG-rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Long-acting PEG-rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 46. Europe Long-acting PEG-rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Long-acting PEG-rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Long-acting PEG-rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Long-acting PEG-rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 50. Asia-Pacific Long-acting PEG-rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Long-acting PEG-rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Long-acting PEG-rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Long-acting PEG-rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 54. Latin America Long-acting PEG-rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Long-acting PEG-rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Long-acting PEG-rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Long-acting PEG-rhG-CSF Sales by Country: 2021 VS 2025 VS 2032 (units) Figure 58. Middle East and Africa Long-acting PEG-rhG-CSF Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Long-acting PEG-rhG-CSF Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Long-acting PEG-rhG-CSF Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Long-acting PEG-rhG-CSF Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Long-acting PEG-rhG-CSF Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Innovative Drugs
  • Generic Drugs
Applications
  • Blood Disorders
  • Neoplastic Diseases
  • Others
Companies covered
  • CSPC
  • Sandoz (Novartis)
  • Qilu Pharmaceutical
  • Mylan
  • Pfizer
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Amgen Inc.
  • Coherus BioSciences, Inc.
  • Biocon Biologics Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting PEG-rhG-CSF Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Long-acting PEG-rhG-CSF Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Long-acting PEG-rhG-CSF Market by Type
  6. 1.3.1 Innovative Drugs
  7. 1.3.2 Generic Drugs
  8. 1.4 Global Long-acting PEG-rhG-CSF Market Size by Type
  9. 1.4.1 Global Long-acting PEG-rhG-CSF Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Long-acting PEG-rhG-CSF Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Long-acting PEG-rhG-CSF Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Long-acting PEG-rhG-CSF Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Long-acting PEG-rhG-CSF Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Long-acting PEG-rhG-CSF Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Long-acting PEG-rhG-CSF Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Long-acting PEG-rhG-CSF Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Long-acting PEG-rhG-CSF Industry Trends
  2. 2.2 Long-acting PEG-rhG-CSF Industry Drivers
  3. 2.3 Long-acting PEG-rhG-CSF Industry Opportunities and Challenges
  4. 2.4 Long-acting PEG-rhG-CSF Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Long-acting PEG-rhG-CSF Revenue (2021-2026)
  2. 3.2 Global Top Players by Long-acting PEG-rhG-CSF Sales (2021-2026)
  3. 3.3 Global Top Players by Long-acting PEG-rhG-CSF Price (2021-2026)
  4. 3.4 Global Long-acting PEG-rhG-CSF Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Long-acting PEG-rhG-CSF Major Company Production Sites & Headquarters
  6. 3.6 Global Long-acting PEG-rhG-CSF Company, Product Type & Application
  7. 3.7 Global Long-acting PEG-rhG-CSF Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Long-acting PEG-rhG-CSF Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Long-acting PEG-rhG-CSF Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Long-acting PEG-rhG-CSF Tier 1, Tier 2, and Tier 3
4 Long-acting PEG-rhG-CSF Regional Status and Outlook
  1. 4.1 Global Long-acting PEG-rhG-CSF Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Long-acting PEG-rhG-CSF Historic Market Size by Region
  3. 4.2.1 Global Long-acting PEG-rhG-CSF Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Long-acting PEG-rhG-CSF Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Long-acting PEG-rhG-CSF Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Long-acting PEG-rhG-CSF Forecasted Market Size by Region
  7. 4.3.1 Global Long-acting PEG-rhG-CSF Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Long-acting PEG-rhG-CSF Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Long-acting PEG-rhG-CSF Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Long-acting PEG-rhG-CSF by Application
  1. 5.1 Long-acting PEG-rhG-CSF Market by Application
  2. 5.1.1 Blood Disorders
  3. 5.1.2 Neoplastic Diseases
  4. 5.1.3 Others
  5. 5.2 Global Long-acting PEG-rhG-CSF Market Size by Application
  6. 5.2.1 Global Long-acting PEG-rhG-CSF Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Long-acting PEG-rhG-CSF Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Long-acting PEG-rhG-CSF Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Long-acting PEG-rhG-CSF Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Long-acting PEG-rhG-CSF Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Long-acting PEG-rhG-CSF Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Long-acting PEG-rhG-CSF Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Long-acting PEG-rhG-CSF Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 CSPC
  2. 6.1.1 CSPC Company Information
  3. 6.1.2 CSPC Business Overview
  4. 6.1.3 CSPC Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 CSPC Long-acting PEG-rhG-CSF Product Portfolio
  6. 6.1.5 CSPC Recent Developments
  7. 6.2 Sandoz (Novartis)
  8. 6.2.1 Sandoz (Novartis) Company Information
  9. 6.2.2 Sandoz (Novartis) Business Overview
  10. 6.2.3 Sandoz (Novartis) Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sandoz (Novartis) Long-acting PEG-rhG-CSF Product Portfolio
  12. 6.2.5 Sandoz (Novartis) Recent Developments
  13. 6.3 Qilu Pharmaceutical
  14. 6.3.1 Qilu Pharmaceutical Company Information
  15. 6.3.2 Qilu Pharmaceutical Business Overview
  16. 6.3.3 Qilu Pharmaceutical Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Qilu Pharmaceutical Long-acting PEG-rhG-CSF Product Portfolio
  18. 6.3.5 Qilu Pharmaceutical Recent Developments
  19. 6.4 Mylan
  20. 6.4.1 Mylan Company Information
  21. 6.4.2 Mylan Business Overview
  22. 6.4.3 Mylan Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Mylan Long-acting PEG-rhG-CSF Product Portfolio
  24. 6.4.5 Mylan Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pfizer Long-acting PEG-rhG-CSF Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Jiangsu Hengrui Medicine
  32. 6.6.1 Jiangsu Hengrui Medicine Company Information
  33. 6.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 6.6.3 Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Jiangsu Hengrui Medicine Long-acting PEG-rhG-CSF Product Portfolio
  36. 6.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 6.7 Fresenius Kabi
  38. 6.7.1 Fresenius Kabi Company Information
  39. 6.7.2 Fresenius Kabi Business Overview
  40. 6.7.3 Fresenius Kabi Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Fresenius Kabi Long-acting PEG-rhG-CSF Product Portfolio
  42. 6.7.5 Fresenius Kabi Recent Developments
  43. 6.8 Amgen Inc.
  44. 6.8.1 Amgen Inc. Company Information
  45. 6.8.2 Amgen Inc. Business Overview
  46. 6.8.3 Amgen Inc. Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Amgen Inc. Long-acting PEG-rhG-CSF Product Portfolio
  48. 6.8.5 Amgen Inc. Recent Developments
  49. 6.9 Coherus BioSciences, Inc.
  50. 6.9.1 Coherus BioSciences, Inc. Company Information
  51. 6.9.2 Coherus BioSciences, Inc. Business Overview
  52. 6.9.3 Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Coherus BioSciences, Inc. Long-acting PEG-rhG-CSF Product Portfolio
  54. 6.9.5 Coherus BioSciences, Inc. Recent Developments
  55. 6.10 Biocon Biologics Inc.
  56. 6.10.1 Biocon Biologics Inc. Company Information
  57. 6.10.2 Biocon Biologics Inc. Business Overview
  58. 6.10.3 Biocon Biologics Inc. Long-acting PEG-rhG-CSF Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Biocon Biologics Inc. Long-acting PEG-rhG-CSF Product Portfolio
  60. 6.10.5 Biocon Biologics Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Long-acting PEG-rhG-CSF Sales by Country
  2. 7.1.1 North America Long-acting PEG-rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Long-acting PEG-rhG-CSF Sales by Country (2021-2026)
  4. 7.1.3 North America Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032)
  5. 7.2 North America Long-acting PEG-rhG-CSF Market Size by Country
  6. 7.2.1 North America Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Long-acting PEG-rhG-CSF Market Size by Country (2021-2026)
  8. 7.2.3 North America Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Long-acting PEG-rhG-CSF Sales by Country
  2. 8.1.1 Europe Long-acting PEG-rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Long-acting PEG-rhG-CSF Sales by Country (2021-2026)
  4. 8.1.3 Europe Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Long-acting PEG-rhG-CSF Market Size by Country
  6. 8.2.1 Europe Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Long-acting PEG-rhG-CSF Market Size by Country (2021-2026)
  8. 8.2.3 Europe Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Long-acting PEG-rhG-CSF Sales by Country
  2. 9.1.1 Asia-Pacific Long-acting PEG-rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Long-acting PEG-rhG-CSF Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Long-acting PEG-rhG-CSF Market Size by Country
  6. 9.2.1 Asia-Pacific Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Long-acting PEG-rhG-CSF Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Long-acting PEG-rhG-CSF Sales by Country
  2. 10.1.1 South America Long-acting PEG-rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Long-acting PEG-rhG-CSF Sales by Country (2021-2026)
  4. 10.1.3 South America Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032)
  5. 10.2 South America Long-acting PEG-rhG-CSF Market Size by Country
  6. 10.2.1 South America Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Long-acting PEG-rhG-CSF Market Size by Country (2021-2026)
  8. 10.2.3 South America Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Long-acting PEG-rhG-CSF Sales by Country
  2. 11.1.1 Middle East and Africa Long-acting PEG-rhG-CSF Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Long-acting PEG-rhG-CSF Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Long-acting PEG-rhG-CSF Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Long-acting PEG-rhG-CSF Market Size by Country
  6. 11.2.1 Middle East and Africa Long-acting PEG-rhG-CSF Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Long-acting PEG-rhG-CSF Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Long-acting PEG-rhG-CSF Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Long-acting PEG-rhG-CSF Value Chain Analysis
  2. 12.1.1 Long-acting PEG-rhG-CSF Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Long-acting PEG-rhG-CSF Production Mode & Process
  7. 12.2 Long-acting PEG-rhG-CSF Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Long-acting PEG-rhG-CSF Distributors
  10. 12.2.3 Long-acting PEG-rhG-CSF Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst